Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2014)
23 slides from Vita Life Sciences's shareholder meeting presentation, May 22, 2014
Slide 1: Welcome to the 2014 Annual General Meeting
Welcome to the 2014 Vita Life Sciences Limited Annual General Meeting herbscigold Veal ips ig Lives .Since 1947 Vi 22 May 2014
Slide 2: Chairman's Welcome Address
Chairman’s Welcome Address
Slide 3: Agenda
1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer Time
Slide 4: Managing Director's Review
Managing Directors Review
Slide 5: Asia Pacific pharmaceutical and healthcare business overview
Asia Pacific pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements 800 registered sku of vitamin and supplement sold in 8 countries in the Asia Pacific region 2 major brands 1. VitaHealth: products sol
Slide 6: Trusted brand portfolio, established footprint in 8 countries
1 Trusted brand portfolio 2 Established footprint in 8 countries 3 Substantial product portfolio offering 800 sku and growing 4 Platform for sustained growth: operations established in 8 Asia Pacific countries Financially disciplined: 19% 3 year revenue CAGR and expansion into 4 new Asian 5 markets
Slide 7: Vita Life Sciences thinks internationally but acts locally
Insert VH logo Insert HoG logo Insert VL logo Country presence Malaysia Australia Malaysia Singapore Hong Kong China Thailand Vietnam Indonesia Total no. of products (sku) on ~450 ~200 ~30 sale Product offering Supplements Vitamins Minerals Meal replacement Market channels He
Slide 8: Product development to distribution value chain
Product Product R&D testing Product registration Approved Product Contract manufacturing, Packing & Distribution Training, Marketing & Sales Note: Packaging & distribution activities undertaken in part by Vita Life Sciences and in part by the contract manufacturers and distributors. 7
Slide 9: Population and business by country
Business 2013 Population Commenced Revenue (m) (A$m) Australia 23 1989 14.2 Malaysia 29 2000 12.3 Singapore 5 1947* 5.7 Hong Kong 7 2006 Thailand 67 2007 China 1,351 2008 3.2 Vietnam 89 2010 Indonesia 247 2015 * As a retail pharmacy. 8
Slide 10: Revenue by geography 2010 vs 2013
2010 revenue by geography 2013 revenue by geography Other Asia 4% Other Asia 15% Singapore 19% Australia Australia Singapore 40% Asia 45% Asia 16% 55% 60% Malaysia OTC Malaysia 32% OTC 29% Total revenue: $21m Total revenue: $35m Thailand, Vietnam, Indonesia, China and Hong Kong are expected to contr
Slide 11: Revenue, EBIT and DPS
Revenue EBIT DPS (A$m) (A$m) (cps) 6 35 3.00 30 24 21 3 1.00 1 1 0.50 0.50 2010 2011 2012 2013 2010 2011 2012 2013 2010 2011 2012 2013 10
Slide 12: Footprint in countries in Asia Pacific
Footprint in 8 countries in Asia Pacific Strategically positioned to grow with the rapid emergence of the Asian middle class that is health conscious with increasing discretionary spending power Australia: Population of 23m; Approximately 7,000 pharmacies and 1,200 health food stores plus groc
Slide 13: Kick Off Meeting & Dinner
bHealth’| Kick Off Meeting & Dinner 2-4 January 2014 '‘DUCATE BUCCEED | > Human Capital (Malaysia & Singapore) Kick Off Meeting & Dinner VitaHealth PRN Or EDUCATE BUCCEED > 12
Slide 14: 2014 Strategic initiatives
2014 Strategic initiatives New consolidated Malaysian premises Indonesia: continued to register products in preparation for commencement of operations Trading update Benefits of an enlarged Asia Pacific platform continue to be realized. New markets entered under current management continue to
Slide 15: Appendix
Appendix
Slide 16: Year ended 31 December results
Year ended 31 December 2013 2012 Change $m $m % Revenue 35.41 30.19 17% EBITDA 5.62 2.93 92% EBIT 5.51 2.86 93% Profit Before Tax 5.52 2.84 94% Profit After Tax 4.75 2.32 105% EPS (Diluted - cents) 8.42 4.14 103% Dividend (cents/share) 3.00 1.00 200% 15
Slide 17: Balance Sheet
Balance Sheet ($ m) 2013 2012 Current assets 20.49 15.58 Non-current assets 1.52 1.23 Total assets 22.01 16.81 Current liabilities (5.68) (5.42) Non-current liabilities (0.06) (0.05) Total liabilities (5.74) (5.47) Net assets 16.27 11.34 16
Slide 18: Cash Flow
Cash Flow ($ m) 2013 2012 Receipts from customers 38.86 32.74 Payments to suppliers and employees (33.54) (31.12) Gross operating cash flow 5.32 1.62 EBITDA 5.62 2.93 Ratio of gross operating cash flow to EBITDA 94.7% 55.3% Net interest received (paid) 0.07 0.04 Income tax paid (0.56) (0.27) Operati
Slide 19: Agenda
1. Chairman’s Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer Time
Slide 20: Resolutions: Re-election of Director – Henry Townsing
1. Remuneration Report 2. Re-election of Director – Henry Townsing 3. Share buy-back 4. Long Term Incentive Plan
Slide 21: Proxy results
PROXY’S RESOLUTIONS IN FAVOUR AGAINST ABSTAIN TOTALS DISCRETION 1) Adoption of the Remuneration 30,254,874 10,600 3,036,476 44,621 33,346,571 Report 2) Election of Director (Mr H Townsing) 33,048,252 - 253,698 44,621 33,346,571 3) Long Term Incentive Plan 31,849,828 14,350 1,437,772 44,621 33,346,57
Slide 22: Contact Details
Contact Details Telephone: +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 21
Slide 23: Disclaimer
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis